Symptomtext
loss of peripheral vision; extreme light sensitivity; Initial information regarding an unsolicited valid non-serious case was received from a Pharmacist via consumer/non-health care professional via physician via Medical Information (Reference number- 00836974) and transmitted to Sanofi on 01-Nov-2021 in a specific country. This case involves a 36-year-old male patient who experienced loss of peripheral vision (visual field defect) and extreme light sensitivity (photophobia) after receiving INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT]. The patient's past vaccination(s) included INFLUENZA for prophylactic vaccination without any adverse events. The patient's medical history, medical treatment(s) and family history were not provided. Patient had no other vaccines On 01-Nov-2021, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B VACCINE produced by Sanofi Pasteur (lot number: UT7384JA and expiry date: 30-Jun-2022) via unknown route in unknown administration site for prophylactic vaccination. On 01-Nov-2021, the patient developed a non-serious loss of peripheral vision (visual field defect) and extreme light sensitivity (photophobia) (unknown latency) about 20 minutes following the administration of INFLUENZA QUADRIVAL A-B VACCINE. It was reported "Pharmacist who works for Johnson and Johnson heard from her brother-in-law that he experienced a reaction about 20 minutes after receiving FLUZONE QUADRIVALENT about 2 hours ago. Have reactions such as this been reported? The pharmacist state, "he called me and reported loss of peripheral vision and extreme light sensitivity about 20 minutes after receiving the vaccine." She stated that the reaction did not seem to be related to possible syncope and seemed "different". She did not have information about the National Drug Code (NDC), presentation or injection site. She said the reaction was "dissipating" and is not now as bad as was" No laboratory data was provided. It was not reported if the patient received any corrective treatment for the events. At time of reporting, the patient was recovering from the events.